Serigen Mediproducts develops silk protein-based medical products and a next-gen tissue regeneration platform applied to orthopaedics, breast cancer and advanced wound care. Its portfolio includes Seriderm, an advanced wound care product that has secured CDSCO approval for treating diabetic foot ulcers. The company is ISO 13485 certified and says it conducted the world’s first clinical trial using silk for bone repair. Serigen plans to use recent funding to scale manufacturing and sales, expand its team, and strengthen its intellectual property portfolio. It is a 2015 spin-off of CSIR-National Chemical Laboratory, incubated at Pune’s Venture Center and headquartered in Pune. The company aims to reduce market dependence on foreign suppliers while expanding clinical deployment of its patented silk-based platform.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2023